Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Kiran Madura
Rbhs Robert Wood Johnson Medical School, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
RBHS-ROBERT WOOD JOHNSON MEDIC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Madura holds equity interest and is the founder and acting CEO in a start-up company characterizing the ubiquitin/proteasome system to identify disease-specific biomarkers and targets for drug discovery in human diseases, and to develop diagnostic assays for use in the animal science industry. The company does not have any value at this time. Dr. Madura is also author of several of several patents and patents applications licensed by CellXplore Inc. from UMDNJ/Rutgers, on new methods for probing the ubiquitin/proteasome system. These patents do not have any IP value at this time. The current NIH grant is to characterize the yeast Rad23 protein which traffics multiubiquitinated proteins to the proteasome, and to investigate the role of the ubiquitin proteasome system in nucleotide excision repair. Since the subject matters of the grant, and of the company and patents utilize proteasome-based assays, the ICOI committee concluded that, while there might not be any direct overlap, sufficient relatedness existed to warrant the existence of the perception of a conflict of interest.
Functional Analysis of Rad23 Protein
The primary objective of the proposed studies is to investigate the role of protein degradation in DNA repair. Xeroderma pigmentosum and Cockayne Syndrome are well studied DNA repair defects for which there is no treatment or cure. Our studies could pave the way towards identification of candidate proteins and biochemical functions that can be targeted by therapeutic agents.
Filed on September 26, 2013.
Tell us what you know about Kiran Madura's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Kiran Madura filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Kiran Madura | Rbhs Robert Wood Johnson Medical School | Conflict of Interest | RBHS-ROBERT WOOD JOHNSON MEDIC | $0 - $4,999 |
| Kiran Madura | Rbhs Robert Wood Johnson Medical School | Conflict of Interest | RBHS-ROBERT WOOD JOHNSON MEDIC | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.